{"nctId":"NCT00696800","briefTitle":"A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)","startDateStruct":{"date":"2006-06-27","type":"ACTUAL"},"conditions":["In Vitro Fertilization"],"count":1509,"armGroups":[{"label":"150 Âµg Corifollitropin Alfa","type":"EXPERIMENTAL","interventionNames":["Drug: Corifollitropin alfa","Drug: Placebo RecFSH / follitropin beta","Biological: RecFSH / Follitropin beta (Days 8 to hCG)","Drug: Ganirelix","Biological: hCG","Biological: Progesterone"]},{"label":"200 IU recFSH","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: RecFSH / Follitropin beta (Days 1 to 7)","Drug: Placebo Corifollitropin alfa","Biological: RecFSH / Follitropin beta (Days 8 to hCG)","Drug: Ganirelix","Biological: hCG","Biological: Progesterone"]}],"interventions":[{"name":"Corifollitropin alfa","otherNames":["MK-8962","SCH 900962","Org 36286"]},{"name":"RecFSH / Follitropin beta (Days 1 to 7)","otherNames":["Puregon / Follistim AQ Cartridge"]},{"name":"Placebo Corifollitropin alfa","otherNames":[]},{"name":"Placebo RecFSH / follitropin beta","otherNames":[]},{"name":"RecFSH / Follitropin beta (Days 8 to hCG)","otherNames":["Puregon / Follistim AQ Cartridge"]},{"name":"Ganirelix","otherNames":["Orgalutran/ Ganirelix Acetate Injection"]},{"name":"hCG","otherNames":["Pregnyl / urinary hCG"]},{"name":"Progesterone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Females of couples with an indication for Controlled Ovarian Stimulation (COS) and in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI);\n* \\>=18 and \\<=36 years of age at the time of signing informed consent;\n* Body weight \\> 60 and \\<=90 kg and body mass index (BMI) \\>=18 and \\<=32 kg/m\\^2;\n* Normal menstrual cycle length: 24-35 days;\n* Availability of ejaculatory sperm (use of donated and/or cryopreserved sperm is allowed);\n* Willing and able to sign informed consent.\n\nExclusion Criteria:\n\n* History of/or any current (treated) endocrine abnormality;\n* History of ovarian hyper-response or ovarian hyperstimulation syndrome\n\n(OHSS);\n\n* History of/or current polycystic ovary syndrome (PCOS);\n* More than 20 basal antral follicles \\<11 mm (both ovaries combined) as measured on ultrasound scan (USS) in the early follicular phase (menstrual cycle day 2-5);\n* Less than 2 ovaries or any other ovarian abnormality (including endometrioma \\> 10 mm; visible on USS);\n* Presence of unilateral or bilateral hydrosalphinx (visible on USS);\n* Presence of any clinically relevant pathology affecting the uterine cavity or fibroids \\>=5 cm;\n* More than three unsuccessful IVF cycles since the last established ongoing pregnancy (if applicable);\n* History of non- or low ovarian response to FSH/ human menopausal gonadotropin (hMG) treatment;\n* History of recurrent miscarriage (3 or more, even when unexplained);\n* FSH \\> 12 IU/L or LH \\> 12 IU/L as measured by the local laboratory (sample taken during the early follicular phase: menstrual cycle day 2-5);\n* Any clinically relevant abnormal laboratory value based on a sample taken during the screening phase;\n* Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts);\n* Recent history of/or current epilepsy, human immunodeficiency virus (HIV) infection, diabetes, cardiovascular, gastro-intestinal, hepatic, renal or pulmonary disease;\n* Abnormal karyotyping of the patient or her partner (if karyotyping is performed);\n* Smoking more than 5 cigarettes per day;\n* History or presence of alcohol or drug abuse within 12 months prior to signing informed consent;\n* Previous use of Org 36286;\n* Use of hormonal preparations within 1 month prior to randomization;\n* Hypersensitivity to any of the concomitant medication prescribed as part of the treatment regimen in this protocol;\n* Administration of investigational drugs within three months prior to signing informed consent.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"36 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With an Ongoing Pregnancy (Ongoing Pregnancy Rate)","description":"An ongoing pregnancy is a fetus with heart activity at least 10 weeks after embryo transfer as assessed by Ultrasound Scan (USS) or Doppler or is confirmed by live birth. The ongoing pregnancy rate is 100 times the number of participants with an ongoing pregnancy after embryo transfer, divided by the total number of participants who started treatment. Calculations were made per attempt, meaning that participants who did not have embryo transfers were considered not pregnant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","spread":null},{"groupId":"OG001","value":"38.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Number of Oocytes Retrieved","description":"Up to 36 hours after receiving hCG, cumulus-oocyte-complexes were retrieved. Mean numbers retrieved were calculated per attempt, meaning that if a participant did not reach this stage in In Vitro Fertilization (IVF) treatment, zero values were imputed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":"8.3"},{"groupId":"OG001","value":"12.6","spread":"6.8"}]}]}]},{"type":"SECONDARY","title":"Median Amount of Recombinant FSH Needed to Induce Multifollicular Development Starting at Day 1","description":"The amount of recFSH administered for a participant to reach 3 follicles \\>= 17 mm, starting from treatment Day 1 onwards.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"400","spread":null},{"groupId":"OG001","value":"1800","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Amount of Recombinant FSH Needed to Induce Multifollicular Development Starting at Day 8","description":"The amount of recFSH administered for a participant to reach 3 follicles \\>= 17 mm, starting from treatment Day 8 onwards.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"400","spread":null},{"groupId":"OG001","value":"400","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum FSH Levels During Stimulation","description":"Mean serum FSH are presented over one Controlled Ovarian Stimulation (COS) cycle: from Day 1 (Pre-dose) up to the day of hCG treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.70","spread":"2.05"},{"groupId":"OG001","value":"6.60","spread":"1.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.49","spread":"6.22"},{"groupId":"OG001","value":"11.61","spread":"3.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.76","spread":"3.18"},{"groupId":"OG001","value":"11.59","spread":"2.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.54","spread":"3.35"},{"groupId":"OG001","value":"11.59","spread":"2.80"}]}]}]},{"type":"SECONDARY","title":"Serum Luteinizing Hormone (LH) Levels During Stimulation","description":"Mean serum LH levels are presented over one COS cycle: from Day 1 (Pre-dose) up to the day of hCG treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.80","spread":"2.02"},{"groupId":"OG001","value":"4.67","spread":"1.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.62","spread":"4.60"},{"groupId":"OG001","value":"2.23","spread":"2.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.29","spread":"1.80"},{"groupId":"OG001","value":"2.05","spread":"1.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.38","spread":"1.79"},{"groupId":"OG001","value":"1.86","spread":"1.63"}]}]}]},{"type":"SECONDARY","title":"Serum Estradiol (E2) Levels During Stimulation","description":"Mean serum E2 levels are presented over one COS cycle: from Day 1 (Pre-dose) up to the day of hCG treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126.13","spread":"39.17"},{"groupId":"OG001","value":"124.79","spread":"37.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1859.39","spread":"1224.78"},{"groupId":"OG001","value":"1392.97","spread":"895.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3700.92","spread":"2837.41"},{"groupId":"OG001","value":"3750.96","spread":"2600.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5486.67","spread":"3461.92"},{"groupId":"OG001","value":"5154.88","spread":"2999.48"}]}]}]},{"type":"SECONDARY","title":"Serum Progesterone (P) Levels During Stimulation","description":"Mean serum P levels are presented over one COS cycle: from Day 1 (Pre-dose) up to day of hCG treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":"1.28"},{"groupId":"OG001","value":"1.85","spread":"1.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.13","spread":"1.97"},{"groupId":"OG001","value":"1.61","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.95","spread":"1.06"},{"groupId":"OG001","value":"2.64","spread":"1.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.20","spread":"4.88"},{"groupId":"OG001","value":"3.16","spread":"1.47"}]}]}]},{"type":"SECONDARY","title":"Serum Inhibin-B Levels During Stimulation","description":"Mean serum Inhibin-B levels are presented over one COS cycle: from Day 1 (Pre-dose) up to day of hCG treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.78","spread":"29.29"},{"groupId":"OG001","value":"52.95","spread":"27.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"488.54","spread":"380.13"},{"groupId":"OG001","value":"493.86","spread":"329.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"578.21","spread":"508.40"},{"groupId":"OG001","value":"642.27","spread":"464.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"608.35","spread":"489.52"},{"groupId":"OG001","value":"612.19","spread":"435.26"}]}]}]},{"type":"SECONDARY","title":"Number of Follicles Categorized by Size on Stimulation Day 1","description":"Ovaries were assessed during stimulation by ultrasonographic investigation (USS), and the mean number of follicles are categorized by their size.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.3"},{"groupId":"OG001","value":"0.1","spread":"0.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.2"},{"groupId":"OG001","value":"0.0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.2"},{"groupId":"OG001","value":"0.0","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Number of Follicles Categorized by Size on Stimulation Day 5","description":"Ovaries were assessed during stimulation by USS, and the mean number of follicles are categorized by their size.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"3.8"},{"groupId":"OG001","value":"4.7","spread":"3.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.7"},{"groupId":"OG001","value":"0.4","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.3"},{"groupId":"OG001","value":"0.1","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Number of Follicles Categorized by Size on Stimulation Day 8","description":"Ovaries were assessed during stimulation by USS, and the mean number of follicles are categorized by their size.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":"6.7"},{"groupId":"OG001","value":"11.6","spread":"6.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"4.6"},{"groupId":"OG001","value":"5.2","spread":"4.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"2.9"},{"groupId":"OG001","value":"2.5","spread":"2.8"}]}]}]},{"type":"SECONDARY","title":"Number of Follicles Categorized by Size on the Day of hCG","description":"Ovaries were assessed during stimulation by USS, and the mean number of follicles are categorized by their size.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":"7.0"},{"groupId":"OG001","value":"13.9","spread":"6.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":"4.8"},{"groupId":"OG001","value":"8.7","spread":"4.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"3.2"},{"groupId":"OG001","value":"5.6","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Number of Cumulus-oocyte-complexes","description":"Prior to IVF the mean number of cumulus-oocyte-complexes used for IVF was assessed","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","spread":"8.2"},{"groupId":"OG001","value":"12.8","spread":"7.0"}]}]}]},{"type":"SECONDARY","title":"Number of Oocytes Assessed Prior to Intracytoplasmic Sperm Injection (ICSI)","description":"The number of oocytes used for ICSI was assessed, and categorized based on their quality","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":"7.7"},{"groupId":"OG001","value":"12.2","spread":"6.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.5"},{"groupId":"OG001","value":"0.9","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":"6.5"},{"groupId":"OG001","value":"9.2","spread":"5.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"1.9"},{"groupId":"OG001","value":"1.7","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Fertilized Oocytes (Fertilization Rate)","description":"The fertilization rate is 100 times the number of fertilized 2 pro-nuclei (2PN) oocytes obtained, divided by the number of oocytes fertilized by IVF or ICSI","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.0","spread":"23.5"},{"groupId":"OG001","value":"67.6","spread":"22.9"}]}]}]},{"type":"SECONDARY","title":"Number of Embryos Obtained on Day 3 Categorized by Quality","description":"Embryos obtained on Day 3 were categorized by their qualiity as follows: Grade 1: excellent: No fragmentation, 6-10 cells, and equal blastomere size taking the impact of cell division into account. Grade 2: good: \\< 20% fragmentation, 6-10 cells, and equal blastomere size taking the impact of cell division into account. Grade 3: fair: 20-50% fragmentation and/or less than 6 cells and/or multinucleation (if observed). Other Grade: Embryos that do not qualify as Grades 1, 2 or 3. Grades 1 and 2 are considered good quality.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":"5.5"},{"groupId":"OG001","value":"7.5","spread":"4.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"4.3"},{"groupId":"OG001","value":"4.5","spread":"3.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"3.4"},{"groupId":"OG001","value":"2.5","spread":"3.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"2.5"},{"groupId":"OG001","value":"2.0","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"2.6"},{"groupId":"OG001","value":"2.0","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"2.2"},{"groupId":"OG001","value":"1.1","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Number of Embryos Transferred on Day 3","description":"After fertilization, the mean number of embryos transferred on Day 3 were assessed. Total and good quality embryos are presented, with good quality embryos, Grades 1 and 2, defined as the following: Grade 1: excellent: No fragmentation, 6-10 cells, and equal blastomere size taking the impact of cell division into account. Grade 2: good: \\< 20% fragmentation, 6-10 cells, and equal blastomere size taking the impact of cell division into account.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.4"},{"groupId":"OG001","value":"1.7","spread":"0.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.7"},{"groupId":"OG001","value":"1.4","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Gestational Sacs (Implantation Rate)","description":"The implantation rate is 100 times the number of gestational sacs assessed by USS after embryo transfer, divided by the number of embryos transferred.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.2","spread":"41.6"},{"groupId":"OG001","value":"32.2","spread":"40.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Miscarriage (Miscarriage Rate) Per Clinical Pregnancy","description":"The miscarriage rate is 100 times the number of miscarriages, divided by the number of clinical pregnancies assessed by USS. A clinical pregnancy is the presence of at least one gestational sac or confirmed by live birth.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":null},{"groupId":"OG001","value":"6.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Miscarriage (Miscarriage Rate) Per Vital Pregnancy","description":"The miscarriage rate is 100 times the number of miscarriages, divided by the number of vital pregnancies assessed by USS. A vital pregnancy is the presence of at least one fetus with heart activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Biochemical Pregnancy (Pregnancy Rate) Per Attempt","description":"Biochemical pregnancy was assessed by measuring serum or urinary hCG. Per attempt means that if a participant did not reach the stage of pregnancy assessment zero values were imputed. The pregnancy rate is 100 times the number of participants with pregnancies detected, divided by the number of participants assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null},{"groupId":"OG001","value":"46.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Biochemical Pregnancy (Pregnancy Rate) Per Embryo Transfer","description":"Biochemical pregnancy was assessed for participants who had embryo transfer by measuring serum or urinary hCG. The pregnancy rate is 100 times the number of participants with pregnancies detected, divided by the number of participants assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.2","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":755},"commonTop":["Procedural pain","Headache","Pelvic pain","Pelvic discomfort","Nausea"]}}}